For the readers interested in the stock health of ZIOPHARM Oncology Inc. (ZIOP). It is currently valued at $3.33. When the transactions were called off in the previous session, Stock hit the highs of $3.165, after setting-off with the price of $3.12. Company’s stock value dipped to $3.015 during the trading on the day. When the trading was stopped its value was $3.04.
Recently in News on January 14, 2021, Ziopharm Oncology Announces Election of James Huang as Chairman of the Board of Directors. – Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation –. You can read further details here
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
ZIOPHARM Oncology Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.32 on 01/14/21, with the lowest value was $2.52 for the same time period, recorded on 01/04/21.
ZIOPHARM Oncology Inc. (ZIOP) full year performance was -36.27%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, ZIOPHARM Oncology Inc. shares are logging -34.83% during the 52-week period from high price, and 85.52% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.79 and $5.11.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1064607 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the ZIOPHARM Oncology Inc. (ZIOP) recorded performance in the market was 20.63%, having the revenues showcasing 10.95% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 634.93M, as it employees total of 73 workers.
Analysts verdict on ZIOPHARM Oncology Inc. (ZIOP)
During the last month, 0 analysts gave the ZIOPHARM Oncology Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.68, with a change in the price was noted +0.36. In a similar fashion, ZIOPHARM Oncology Inc. posted a movement of +12.54% for the period of last 100 days, recording 1,737,418 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ZIOP is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
ZIOPHARM Oncology Inc. (ZIOP): Technical Analysis
Raw Stochastic average of ZIOPHARM Oncology Inc. in the period of last 50 days is set at 92.11%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 89.29%. In the last 20 days, the company’s Stochastic %K was 84.18% and its Stochastic %D was recorded 84.30%.
Let’s take a glance in the erstwhile performances of ZIOPHARM Oncology Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 20.63%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -10.85%, alongside a downfall of -36.27% for the period of the last 12 months. The shares increased approximately by 4.47% in the 7-day charts and went down by 9.75% in the period of the last 30 days. Common stock shares were driven by 10.95% during last recorded quarter.